我想看一级黄色片_欧美性爱无遮挡电影_色丁香视频网站中文字幕_视频一区 视频二区 国产,日本三级理论日本电影,午夜不卡免费大片,国产午夜视频在线观看,18禁无遮拦无码国产在线播放,在线视频不卡国产在线视频不卡 ,,欧美一及黄片,日韩国产另类

New data from Pfizer and BioNTech shows that the COVID-19 vaccine produced by the two firms remains effective when stored at normal freezer temperatures for two weeks, potentially greatly easing vaccine distribution in the U.S. and around the world.

New research and analysis also shows that the first dose of the Pfizer vaccine is highly effective at preventing COVID-19. Two Canadian researchers claim the first dose shows 92.6% efficacy, compared with 95% efficacy after both doses. The researchers say these results should be used to reassess how limited vaccine supply is distributed.

Under the Pfizer/BioNTech vaccine’s initial FDA Emergency Use Authorization, the vaccine had to be stored at –70°C, a temperature that required expensive and specialized freezers to achieve. Before the pandemic, that equipment was hard to find save for freezers housed in research facilities.

That created added headaches, costs, and risks—particularly for rural or remote vaccination facilities. Pfizer developed a shipping box cooled by dry ice that could maintain the temperatures for a limited time. But experts have expressed concern about potential spoilage of doses stored using this low-tech method.

But new data from the companies shows that the vaccine retains its effectiveness for at least two weeks when stored at temperatures of between –15°C and –25°C, easily achieved by standard medical storage freezers.

The new data has been submitted to the FDA, but changes to current storage standards must be approved as part of a revised Emergency Use Authorization before any changes are made to distribution methods on the ground.

Experts have been expecting Pfizer to pursue approval for less stringent storage requirements. The initial ultracold requirements were the product of a compressed development timeline, with further long-term research and testing needed before they could be loosened.

Based on their findings on the very high protectiveness of the Pfizer/BioNTech vaccine, researchers Danuta Skowronski and Gaston De Serres say that “the benefits derived from a scarce supply of vaccine could be maximized by deferring second doses until all priority group members are offered at least one dose.” This approach was tried early in the U.K. as part of efforts to speed vaccinations, helping it achieve the third-highest national first-dose vaccination rate in the world.

But this new data must also make its way through U.S. regulatory channels before any changes are made to vaccine distribution. One looming uncertainty is how long the first-dose immunity lasts without the second dose, which effectively helps reinforce what a recipient’s immune system learns from the first dose.

There was already preliminary evidence in early February that the AstraZeneca vaccine, created in conjunction with the University of Oxford, cut transmission rates for the virus by about two-thirds with just a single dose.

That data will soon be confirmed, reports the Telegraph, citing sources from Public Health England (PHE), not just for the AstraZeneca vaccine but for a single dose of the two-dose Pfizer vaccine as well. And that protection against transmission appears consistent across all age groups.

This adds to evidence from two Israeli studies published this week, finding that Pfizer’s COVID vaccine significantly reduces the virus’s transmission. The joint analysis between Pfizer and Israel’s health ministry found that a two-dose regimen of the shot reduced infections by 89.4% overall (including asymptomatic cases) and 93.7% in symptomatic cases. Results were tracked via testing for COVID infections, fueled by a national COVID-tracking database in Israel. The study has yet to be peer-reviewed.

The second study examined more than 7,000 hospital staff and found about a 75% reduction in infections with Pfizer’s vaccine.

Given the high efficacy rates of the Pfizer, Moderna, J&J, and AstraZeneca vaccines, getting some kind of shot would still weaken the virus and at the very least lower the chances of spreading it to others.

We already know that these vaccines significantly reduce the risk of COVID-related hospitalization and deaths for those who may go on to contract it. But the ideal would be to achieve a significant level of “sterilizing immunity,” the kind that can stop widespread community spread of the coronavirus. And the information rolling in suggests this class of vaccines may meet that challenge.